Rapamycin (Sirolimus) Vaccine Interaction Profile

How Sirolimus Suppresses the Immune System

Sirolimus binds the intracellular protein FKBP12, and the resulting complex inhibits mTORC1, the master regulator of cell growth and proliferation. The Rapamune U.S. Prescribing information states that sirolimus "inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine stimulation." That single mechanism cascades into multiple vaccine-relevant effects.

T-Cell Activation Is Blocked at the G1/S Checkpoint

Antigen-presenting cells activate naive T cells by releasing IL-2. Normally, IL-2 drives those T cells through the G1-to-S phase checkpoint via mTORC1. Sirolimus arrests this transition, reducing clonal expansion of antigen-specific T cells by as much as 70 to 90% in vitro, according to mechanistic data published in Nature Immunology.

Short clonal bursts still occur. Sirolimus does not block early T-cell receptor signaling the way calcineurin inhibitors do, so some antigen recognition proceeds. The problem is that the cells cannot expand to the numbers needed for durable memory.

B-Cell Class Switching and Antibody Quality Suffer

Vaccine efficacy depends on class-switched, high-affinity IgG antibodies. Class switching requires mTORC1-dependent germinal center reactions. A 2021 study in The Journal of Clinical Investigation showed that mTOR inhibition impairs germinal center B-cell survival and reduces somatic hypermutation, the process that refines antibody affinity. The practical result is lower peak antibody titers and faster waning.

Dose Dependency of the Immunosuppressive Effect

Transplant-level troughs (10 to 20 ng/mL) suppress immunity far more completely than the pulsed low doses (1 to 6 mg weekly, producing troughs often <3 ng/mL) used in off-label longevity protocols. A proof-of-concept trial by Mannick et al. Published in Science Translational Medicine found that low-dose or intermittent everolimus (a sirolimus analog) actually enhanced influenza vaccine responses in older adults at some dose levels, raising 20-30% improvements in hemagglutination-inhibition titers compared to placebo. This dose-response nuance is absent from the transplant prescribing information and is not yet reflected in ACIP guidance.

Live-Attenuated Vaccines: A Hard Contraindication

Live-attenuated vaccines are vaccines made from weakened but replication-competent pathogens. They depend on the host mounting a limited immune response to a low-level active infection. When that immune response is pharmacologically suppressed, the pathogen can replicate unchecked.

Which Live Vaccines Are Affected

The list of live vaccines contraindicated under active immunosuppression includes:

• MMR (measles, mumps, rubella)
• Varicella (chickenpox) and zoster live (Zostavax)
• Yellow fever
• Oral typhoid (Ty21a)
• Intranasal influenza (FluMist)
• Oral polio (not used in the U.S., still relevant internationally)
• BCG (tuberculosis; used in >150 countries)
• Smallpox/mpox live vaccine (ACAM2000)

The ACIP General Best Practice Guidelines for Immunization state that "live vaccines should generally not be administered to persons who are immunosuppressed." The Rapamune prescribing information echoes this directly, listing live vaccine avoidance as a labeled precaution.

The Reactivation Risk With Varicella-Zoster

Varicella reactivation (shingles) is a documented complication in sirolimus-treated transplant recipients. A retrospective analysis in Transplantation found herpes zoster incidence of 8.9 per 100 patient-years in sirolimus-based regimens. Administering live Zostavax in this setting risks disseminated zoster. The recombinant subunit vaccine Shingrix (RZV) is the correct alternative: it contains no live virus and is preferred by ACIP for immunocompromised adults.

Timing for Patients Starting Sirolimus Electively

If a patient is beginning sirolimus for an off-label longevity indication and has not received recent live vaccines, the practical window is straightforward. Administer all needed live vaccines at least 4 weeks before starting sirolimus. After stopping sirolimus, wait a minimum of 3 months before giving a live vaccine, because residual immunosuppression persists beyond the last dose. The American Society of Transplantation Infectious Diseases Community of Practice recommends this 3-month washout period for mTOR inhibitors before live vaccine administration.

Inactivated, Subunit, and mRNA Vaccines: Permitted but Attenuated

No safety contraindication applies to inactivated vaccines in sirolimus-treated patients. The clinical concern is reduced efficacy, not danger.

COVID-19 mRNA Vaccines and Sirolimus

Three published studies examined COVID-19 mRNA vaccine responses in solid organ transplant recipients on sirolimus-containing regimens.

• A 2021 letter in NEJM (N=436 transplant recipients) found that only 17% mounted detectable antibody responses after a two-dose mRNA vaccine series, compared with >90% in healthy controls.
• A follow-up study in JAMA (N=658) found that a third mRNA dose raised seroconversion to 49%, still well below immunocompetent rates.
• mTOR inhibitor use specifically (versus calcineurin inhibitors) was associated with lower seroconversion probability in a multivariable model from the Annals of Internal Medicine.

These data apply primarily to transplant-level dosing. No randomized trial has yet measured COVID-19 vaccine antibody titers in patients on pulsed low-dose sirolimus for longevity purposes.

Influenza Vaccine: The Dose-Dependent Exception

The Mannick et al. Rapalog/influenza data mentioned above deserve separate attention. In a Science Translational Medicine trial (N=218), older adults randomized to RAD001 (everolimus) 0.5 mg daily or 5 mg weekly showed significantly improved influenza vaccine responses at 6 weeks versus placebo (P<0.01 for the 0.5 mg daily arm). The 20 mg weekly arm showed no benefit and a trend toward harm.

This is the only randomized controlled trial suggesting an mTOR inhibitor can enhance vaccine immunogenicity. The mechanism may involve mTOR's role in aging-related immunosenescence reversal. An ongoing NIA-funded trial (NCT04326894) is testing low-dose rapamycin specifically on influenza vaccine responses in older adults.

Pneumococcal, Hepatitis B, and HPV Vaccines

Blunted responses have been documented with:

• Pneumococcal vaccines (PPSV23 and PCV13/PCV15/PCV20): titers reduced roughly 30 to 50% in mTOR-inhibitor-treated transplant cohorts per a review in Clinical Infectious Diseases.
• Hepatitis B vaccine: non-response rates as high as 40% in immunosuppressed patients; a three-dose series followed by titer check is standard practice.
• HPV vaccine (Gardasil 9): data are limited to pediatric transplant populations; reduced geometric mean titers observed in a Pediatric Transplantation study.

Clinicians should order post-vaccination titers 4 to 8 weeks after completing any series to confirm seroprotection.

Recommended Vaccination Schedule for Patients on Sirolimus

The following clinical decision framework synthesizes ACIP guidance, AST/IDSA transplant recommendations, and the Rapamune prescribing information into a practical schedule for HealthRX prescribers.

Pre-Sirolimus Vaccination Audit (At Least 4 Weeks Before First Dose)

1. Confirm MMR immunity (IgG titers or documented two-dose series). Vaccinate if non-immune.
2. Confirm varicella immunity. Vaccinate with two-dose Varivax series if seronegative.
3. Administer Shingrix (RZV) two-dose series if age ≥50 or immunocompromising condition, regardless of prior Zostavax.
4. Administer Tdap if not given in the past 10 years.
5. Administer high-dose influenza vaccine (Fluzone HD) or adjuvanted formulation (Fluad) annually; schedule pre-initiation when possible.
6. Complete hepatitis B series (three-dose Engerix-B or two-dose Heplisav-B) and confirm anti-HBs ≥10 mIU/mL.
7. Administer PCV20 or PCV15 followed by PPSV23 8 weeks later per current ACIP pneumococcal schedule.

During Active Sirolimus Therapy

• Inactivated and mRNA vaccines: administer on schedule.
• Live vaccines: do not give.
• Annual influenza: use inactivated high-dose or adjuvanted formulation; check hemagglutination-inhibition titer 4 weeks post-vaccination if trough is >5 ng/mL.
• Post-vaccination titer checks: hepatitis B (anti-HBs), pneumococcal (IgG to serotypes), and post-COVID booster spike IgG are all reasonable monitoring steps.

After Stopping Sirolimus

Wait at least 3 months before administering any live vaccine. Sirolimus has a half-life of approximately 62 hours in healthy adults (Rapamune label), but its immunosuppressive effects outlast the pharmacokinetic half-life due to downstream transcriptional changes.

Can You Drink Alcohol on Rapamycin (Sirolimus)?

No pharmacokinetic drug-drug interaction between sirolimus and ethanol has been reported in the Rapamune prescribing information or in published interaction databases. Alcohol does not meaningfully inhibit or induce CYP3A4 or P-glycoprotein, the two primary routes of sirolimus metabolism, at typical social-drinking quantities.

Why Caution Still Applies

Sirolimus is hepatically metabolized, and chronic or heavy alcohol use causes liver inflammation and cirrhosis that elevates sirolimus trough levels by impairing CYP3A4 function. A population pharmacokinetics analysis published in Clinical Pharmacokinetics demonstrated that hepatic impairment increased sirolimus AUC by approximately 61%. Any condition that worsens liver function will raise sirolimus exposure above the intended target.

Separately, both sirolimus and alcohol are associated with hyperlipidemia. Sirolimus raises triglycerides in a dose-dependent manner per the Rapamune label (incidence 38 to 45% in de novo transplant trials). Heavy alcohol intake compounds this effect independently.

The practical guidance: moderate alcohol (up to 1 drink/day for women, up to 2 drinks/day for men, per CDC definitions) is unlikely to cause a clinically significant interaction. Binge drinking or chronic heavy use requires dose re-evaluation with trough monitoring.

Other Key Drug Interactions With Sirolimus

Vaccine immunogenicity sits within a broader interaction picture that HealthRX prescribers must review before initiating sirolimus.

Strong CYP3A4/P-gp Inhibitors: Increase Sirolimus Levels

The following drugs can raise sirolimus troughs to potentially toxic levels:

• Ketoconazole, voriconazole, itraconazole (azole antifungals)
• Clarithromycin, erythromycin (macrolide antibiotics)
• Diltiazem, verapamil (calcium channel blockers)
• Grapefruit juice (furanocoumarins inhibit intestinal CYP3A4)

The Rapamune label flags a 10-fold increase in sirolimus AUC with ketoconazole co-administration. Dose reduction of 50 to 90% may be needed.

Strong CYP3A4 Inducers: Decrease Sirolimus Levels

• Rifampin: reduces sirolimus AUC by approximately 82% (Rapamune label).
• Phenytoin, carbamazepine, phenobarbital (antiepileptics).
• St. John's Wort (hypericum perforatum).

Patients starting or stopping these agents need sirolimus trough re-checks within 5 to 7 days.

Calcineurin Inhibitors: Nephrotoxicity Amplification

Combining sirolimus with cyclosporine without dose adjustment increases the risk of calcineurin-inhibitor-associated nephrotoxicity. The Rapamune label recommends separating sirolimus from cyclosporine administration by 4 hours and monitoring renal function closely.

ACE Inhibitors and Angioedema

Post-marketing surveillance data cited in the Rapamune label document angioedema in patients receiving sirolimus plus an ACE inhibitor. This appears to be a pharmacodynamic (not pharmacokinetic) interaction. The combination is not contraindicated but requires patient counseling and prompt evaluation of throat/tongue swelling.

Monitoring Parameters During Sirolimus Therapy

Effective safety oversight requires tracking several parameters concurrently.

Sirolimus Whole-Blood Trough Levels

• Transplant indication target: 4 to 12 ng/mL (maintenance phase per Rapamune label).
• Off-label longevity use: troughs typically <3 ng/mL with weekly pulsed dosing; no validated therapeutic range exists.
• Draw timing: 24 hours after the last dose, before the next dose. At least 5 days after any dose adjustment to allow steady-state.

Lipid Panel

Check fasting lipids at baseline, at 3 months, and every 6 to 12 months. Statin therapy is appropriate for sirolimus-associated hyperlipidemia per standard ACC/AHA cardiovascular risk guidelines.

Complete Blood Count and Renal Function

Sirolimus causes dose-dependent thrombocytopenia, anemia, and may worsen renal function, particularly if proteinuria is present at baseline. A baseline urinalysis with spot urine protein-to-creatinine ratio is recommended before initiating therapy.

Special Populations: What Changes

Older Adults (Age &ge;65)

This group is the primary target of off-label longevity use of rapamycin. The Mannick immunosenescence data suggest potential benefit for vaccine responses at low doses, but older adults also have the highest baseline susceptibility to vaccine-preventable illness. All age-appropriate vaccinations, especially influenza (high-dose), RSV (Abrysvo or Mresvia), pneumococcal, and Shingrix, should be completed before sirolimus initiation.

Renal Transplant Recipients

This is the FDA-approved population. ACIP recommends a full catch-up vaccination audit at transplant listing, with all live vaccines completed before transplant. Post-transplant, live vaccines are permanently deferred in most protocols.

Patients With Active Infection

Sirolimus impairs both innate and adaptive immune responses, so active bacterial, fungal, or viral infection warrants dose interruption and clinical re-evaluation before vaccinations are given or sirolimus is restarted.